Development and evaluation of polysorbate-80 coated Mangiferin PLGA nanoparticles used in the treatment of cerebral ischemia.

To enhance Mangiferin (MNG) the brain bioavailability by developed novel polysorbate-80 (P 80) MNG PLGA NPs and examined the quantity of MNG through developed a novel method of LC–MS/MS in the ischemic rat brain treatment. The solvent evaporation method used to develop a novel MNG loaded PLGA NPs followed by their coating from polysorbate-80. Polysorbate-80 (P 80) MNG PLGA NPs developed based on EE, particle size, Zeta Potential, PDI, and loading capacity with their characterization followed by drug release and intranasal permeation to enhance the brain bioavailability and also determined their neurobehavioral as well as biochemical evaluation with the histopathological examination. P 80 MNG PLGA NPs were optimized with their particle size 103.4 ± 2.66 nm, PDI: 0.201 ± 0.008, Zeta Potential (−35.8 ± 2.48), and drug loading 37.16 ± 2.09% with 76.08 ± 4.91% entrapment efficiency showed a sustained and controlled release (83.43 ± 6.47%) with great permeation (> 83%) of MNG. MNG & IS showed retention time (0.756 and 1.258 min) and their m/z (421.20/301.20 and 237.2/179.2), respectively. MNG showed a good linearity range, i.e., 10.0–1000.0 ng mL−1; the results of inter-and-intraday accuracy and CV were found to be (93.01–99.43%) and (2.27–4.02%), respectively. An excellent significant results was showed, i.e., p < 0.001 for (AUC)0–24 & Cmax via i.n. dose delivered. A highly significantly results of P 80 MNG PLGA NPs (i.n.) were found based on the examination of biochemical, neurobehavioral, and histopathological in the developed ischemic MCAO brain rat's model. An excellent significant role of P 80 MNG PLGA NPs for MNG were proved based on enhancement of brain bioavailability of MNG via i.n. delivery of the rats and targeted easily to the brain in the treatment of cerebral ischemia followed by improvement of neuroprotection based on use of a very small dose of MNG. [ABSTRACT FROM AUTHOR]